The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.本申請案係關於使用與低劑量Pim抑制劑N-{(7R)-4-[(3R,4R,5S)-3-胺基-4-羥基-5-甲基哌啶-1-基]-7-羥基-6,7-二氫-5H-環戊并[b]吡啶-3-基}-6-(2,6-二氟苯基)-5-氟吡啶-2-甲醯胺組合之JAK1/JAK2抑制劑魯索替尼治療骨髓增生性贅瘤，其中該組合在低劑量Pim抑制劑下出乎意料地具有協同作用。
